| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q3 2025 | 3 | 81,319 | BEAM, LYELL IMMUNOPHARMA INC, PRME | 13F-HR | 11/12/2025 | 000119312525277944 |
| Q2 2025 | 3 | 51,899 | BEAM, LYEL, PRME | 13F-HR | 8/14/2025 | 000095012325008264 |
| Q1 2025 | 3 | 58,687 | BEAM, LYEL, PRME | 13F-HR | 5/13/2025 | 000095012325004952 |
| Q4 2024 | 3 | 74,357 | BEAM, LYEL, PRME | 13F-HR | 2/14/2025 | 000095012325002628 |
| Q3 2024 | 3 | 90,299 | BEAM, LYEL, PRME | 13F-HR | 11/8/2024 | 000095012324010641 |
| Q2 2024 | 3 | 91,561 | BEAM, LYEL, PRME | 13F-HR | 8/13/2024 | 000095012324008094 |
| Q1 2024 | 3 | 135,050 | BEAM, LYEL, PRME | 13F-HR | 5/14/2024 | 000095012324005128 |
| Q4 2023 | 3 | 118,877 | BEAM, LYEL, PRME | 13F-HR | 2/14/2024 | 000095012324002084 |
| Q3 2023 | 3 | 103,180 | BEAM, LYEL, PRME | 13F-HR | 11/14/2023 | 000095012323010382 |
| Q2 2023 | 3 | 165,309 | BEAM, LYEL, PRME | 13F-HR | 8/14/2023 | 000095012323007815 |
| Q1 2023 | 3 | 142,027 | BEAM, LYEL, PRME | 13F-HR | 5/15/2023 | 000095012323005049 |
| Q4 2022 | 3 | 195,862 | BEAM, LYEL, PRME | 13F-HR | 2/14/2023 | 000095012323002243 |
| Q3 2022 | 2 | 259,598 | LYEL, BEAM | 13F-HR | 11/14/2022 | 000095012322011914 |
| Q2 2022 | 2 | 222,308 | LYEL, BEAM | 13F-HR | 8/15/2022 | 000095012322008905 |
| Q1 2022 | 2 | 236,299 | BEAM, LYEL | 13F-HR | 5/16/2022 | 000095012322006032 |
| Q4 2021 | 2 | 343,083 | BEAM, LYEL | 13F-HR | 2/14/2022 | 000095012322002933 |
| Q3 2021 | 4 | 824,675 | LYEL, BEAM, RELX, ILMN | 13F-HR | 11/15/2021 | 000095012321015317 |
| Q2 2021 | 4 | 1,017,872 | RELX, LYEL, BEAM, VIR | 13F-HR | 8/16/2021 | 000095012321011383 |
| Q1 2021 | 2 | 205,768 | BEAM, VIR | 13F-HR | 5/17/2021 | 000095012321006871 |
| Q4 2020 | 2 | 157 | BEAM, VIR | 13F-HR | 2/17/2021 | 000095012321002962 |